|
|
|||
|
|||
|
|
|||
|
antegren therapy |
|||
|
|
|||
|
|||
![]()
|
|||
|
|
|||
|
antegren therapy Biogen Idec and Elan Announce Intention to Submit for Approval for Multiple SclerosisBased on One-Year Data The decision to file a Biologics License Application (BLA) was made after discussionswith the FDA of one-year data from the two ongoing two-year Phase III trialsin MS antegren therapy. The companies are committed to completing the two-year trials antegren therapy. To protectthe integrity of the trials, the companies are not disclosing the one-year dataat this time. Biogen Idec and Elan are collaborating equally on the development of natalizumabfor MS, Crohn's disease, and rheumatoid arthritis. About the Antegren MS Clinical Trials About Antegren (natalizumab) |
|||
![]()
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
| aantegren therapy anntegren therapy anttegren therapy anteegren therapy anteggren therapy antegrren therapy antegreen therapy antegrenn therapy antegren therapy antegren ttherapy antegren thherapy antegren theerapy antegren therrapy antegren theraapy antegren therappy antegren therapyy ntegren therapy ategren therapy anegren therapy antgren therapy anteren therapy antegen therapy antegrn therapy antegre therapy antegrentherapy antegren herapy antegren terapy antegren thrapy antegren theapy antegren therpy antegren theray antegren therap a ntegren therapy an tegren therapy ant egren therapy ante gren therapy anteg ren therapy antegr en therapy antegre n therapy antegren therapy antegren therapy antegren t herapy antegren th erapy antegren the rapy antegren ther apy antegren thera py antegren therap y antegren therapy nategren therapy atnegren therapy anetgren therapy antgeren therapy antergen therapy antegern therapy antegrne therapy antegre ntherapy antegrent herapy antegren hterapy antegren tehrapy antegren threapy antegren thearpy antegren therpay antegren therayp aantegren therapy theantegren therapy antegren therapy | |||
|
|
|||
|
|
|||
|
|
|||
|
Copyright 2005 D-S LTD. |